Physiologically based pharmacokinetic (PBPK) modeling is a core element of the early drug and formulation development workflow, enabling data-driven decisions that accelerate timelines and de-risk programs.
GastroPlus® X.2: The Deep Dive Webinar Series – How New AI-Powered Tools Can Support Your PBPK Modeling
What if you could design a complex workflow, then set it into motion with a single click?
Enhancing Drug Formulation Development Through PBBM and GastroPlus®
As anyone who has worked in the pharmaceutical industry knows, there is a constant push to accelerate and optimize development processes.
GastroPlus® X.2: The Deep Dive Webinar Series – Introducing Orchestrator, Automation for Complex PBPK/PBBM Modeling in GPX.2
What if you could design a complex workflow, then set it into motion with a single click?
Exploring Artificial Intelligence’s Potential to Enhance Conventional Anticancer Drug Development
Cancer affects one in three to four people globally, with over 20 million new cases and 10 million deaths annually, projected to rise to 35 million cases by 2050. Developing effective cancer treatments is crucial, but the drug discovery process is a highly complex and expensive endeavor, with success rates sitting well below 10% for oncologic therapies
Get Under the Skin with GPX.2
If you’re working on the development of injectable therapies, then this webinar is for you
Introducing Orchestrator – Faster Workflows, Smarter Science
As scientists working in pre-clinical drug development, we are constantly balancing the need for rigorous, mechanistic modeling with the realities of fast-moving project timelines.
Whole-Body Disposition and Metabolism of [14C]-2,4,4′-Trichlorobiphenyl (PCB28) Following Lung Administration in Rats
Toxicities of lower-chlorinated biphenyls (LC-PCBs) have drawn increasing attention due to growing evidence of their presence in school indoor air, with 2,4,4′-trichlorobiphenyl (PCB28) being a prevalent congener.
QSAR-based Physiologically Based Pharmacokinetic (PBPK) Modeling for 34 Fentanyl Analogs: Model Validation, Human Pharmacokinetic Prediction and Abuse Risk Insights
Fentanyl analogs, as emerging new psychoactive substances (NPS), pose a global public health threat due to widespread abuse, high toxicity, and frequent overdose fatalities.
AI-Driven Knowledge Management in PBPK Modeling: Challenges & Opportunities
High-quality data is the foundation of every major AI advance
Advancing Kidney Safety: What’s New in RENAsym® 2A
Drug-induced kidney injury remains a significant concern in pharmaceutical development, with traditional methods often falling short in predicting renal toxicity across diverse compounds and patient populations.
DILIsym® 11 Product Brochure
Quantitative Systems Toxicology (QST) Software for Predicting and Explaining Drug-Induced Liver Injury (DILI)
The Impact of Simulation-Based Learning on Study Acceleration: Spoken from the Sponsor who Converted
Enhancing Training to be a personalized, representative and interactive strategic asset
Expanding ADMET Predictor®’s Chemical Space: Enhanced bRo5 and Chameleon Molecule Predictions for HTPK
ADMET Predictor has been enhanced to accurately predict properties of beyond Rule-of-Five (bRo5) molecules, including macrocycles and PROTACs.
Formulation and Evaluation of Poly(Jasmine Lactone) Based Micelles for Improving the Oral Permeability of Acyclovir
Acyclovir (ACV), an antiviral drug, belongs to the BCS class III drug with intermediate solubility and low permeability.
Sensitivity Analysis of the Inputs for Bioactivity-Exposure Ratio Calculations in a NAM-based Systemic Safety Toolbox
To support regulatory decision-making without animal testing, Next-Generation Risk Assessment (NGRA) frameworks leverage New Approach Methodologies (NAM).
3 Mistakes We’re Still Making with Study Training (and How to Fix Them)
Training is one of the most critical parts of study start-up and yet, we often treat it like a box to check rather than the foundation of trial quality.
Thales™ Product Brochure
Accelerate your model development
Unlocking the Power of Predictive Toxicology: What’s New in DILIsym® 11
Introducing DILIsym® 11, the latest evolution of the industry’s leading quantitative systems toxicology (QST) platform.